Go Back
Oryzon
ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.
More Details
Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization.
ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.